Yes, tirzepatide is FDA-approved for weight loss. On November 8, 2023, the FDA approved tirzepatide under the brand name Zepbound specifically for chronic weight management in adults. It’s a once-weekly injection used alongside a reduced-calorie diet and increased physical activity.
Who Qualifies for a Prescription
Zepbound is approved for two groups of adults. The first is people with obesity, defined as a BMI of 30 or higher. The second is people with overweight (BMI of 27 or higher) who also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
The FDA also approved Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity. This makes it one of the few weight loss medications with a specific approval tied to a sleep-related condition.
Tirzepatide was already on the market before the weight loss approval. It first launched as Mounjaro, approved for managing blood sugar in type 2 diabetes. Zepbound is the same molecule, same manufacturer (Eli Lilly), but marketed separately for weight management.
How Much Weight People Lose
The landmark trial behind the approval, called SURMOUNT-1, tested three dose levels in people with obesity who did not have diabetes. The results were striking. Participants on the lowest dose (5 mg) lost an average of 35 pounds. Those on the middle dose (10 mg) lost about 49 pounds. And the highest dose (15 mg) produced an average loss of roughly 52 pounds, or 22.5% of starting body weight.
Overall, participants lost between 16% and 22.5% of their body weight depending on the dose. These numbers made tirzepatide one of the most effective weight loss medications ever tested in clinical trials.
How It Compares to Semaglutide
Semaglutide (sold as Wegovy for weight loss) was the previous standout in this drug class. A recent systematic review and meta-analysis directly comparing the two found that tirzepatide produces significantly greater weight loss. On average, people taking tirzepatide lost about 4.6 percentage points more body weight and roughly 10.5 additional pounds compared to those on semaglutide.
The differences were even more pronounced at higher weight loss thresholds. People on tirzepatide were nearly three times as likely to lose 15% or more of their body weight and more than twice as likely to reach the 20% mark. Both medications are injected once a week under the skin, so the treatment experience is similar.
Why It Works Differently
Most weight loss injections in this class target a single gut hormone pathway. Tirzepatide targets two: GLP-1 and GIP. Both hormones are naturally released after eating and help regulate appetite, blood sugar, and how your body stores fat. By activating both pathways simultaneously, tirzepatide appears to suppress appetite more effectively and influence fat metabolism in ways that a single-target drug does not.
Research published in PNAS found that tirzepatide also activates one of these pathways in an unusual way that causes less receptor burnout over time. The GIP component is thought to act on fat tissue and metabolic control centers in the brain, which likely contributes to the extra weight loss beyond what GLP-1 drugs alone achieve.
Dosing and What to Expect
Treatment starts at 2.5 mg once per week, which is not a maintenance dose. It’s designed to let your body adjust. After four weeks, the dose increases to 5 mg. From there, your prescriber can continue raising it by 2.5 mg increments every four weeks or longer, up to a maximum of 15 mg. Maintenance doses for weight loss are 5 mg, 10 mg, or 15 mg, depending on how you respond and what you tolerate.
The gradual titration matters because it significantly reduces side effects. Jumping to a high dose immediately would cause far more nausea and digestive discomfort than easing into it over several weeks.
Common Side Effects
Digestive issues are by far the most frequent complaint. In adverse event reports, nausea was the most common side effect at 27.7%, followed by diarrhea (12.8%), vomiting (10.6%), constipation (8.1%), and upper abdominal pain (4.9%). These tend to be worst during the early weeks of treatment and during dose increases, then improve as your body adjusts.
For most people, the gastrointestinal effects are mild to moderate and temporary. Eating smaller meals, avoiding fatty foods, and staying hydrated can help manage symptoms during the adjustment period.
Safety Warnings and Contraindications
Tirzepatide carries a boxed warning, the most serious type the FDA issues, regarding thyroid tumors. In rat studies, the drug caused thyroid C-cell tumors at doses similar to those used in humans. Whether this translates to a risk in people remains unknown, but the warning exists as a precaution.
Because of this, tirzepatide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, shortness of breath, or persistent hoarseness while taking the medication, those are symptoms worth reporting to your prescriber promptly. The drug is also off-limits for anyone with a known serious allergy to tirzepatide or its ingredients.